Most cited papers from UCB Pharma (Belgium)

UCB Pharma (Belgium)

What are the most cited papers from UCB Pharma (Belgium)?

The most cited paper from UCB Pharma (Belgium) is "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016" (Andrew Rhodes et al., 2017), with 3,822 citations. Next come "Romosozumab Treatment in Postmenopausal Women with Osteoporosis" (1,797) and "The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam" (1,624).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 239 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 Andrew Rhodes et al. · Critical Care Medicine Open access	18 Jan 2017	3,822
2	Romosozumab Treatment in Postmenopausal Women with Osteoporosis Felicia Cosman, Daria B. Crittenden, Jonathan Derrick Adachi et al. · New England Journal of Medicine Open access	18 Sep 2016	1,797
3	The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Berkley A. Lynch, Nathalie Lambeng, Karl H. Nocka et al. · Proceedings of the National Academy of Sciences Open access	21 Jun 2004	1,624
4	Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis Kenneth G. Saag, JEFFREY E. PETERSEN, Maria Luisa Brandi et al. · New England Journal of Medicine Open access	11 Sep 2017	1,528
5	Prevalence and rate of diagnosis of allergic rhinitis in Europe Vincent Bauchau, Stephen R. Durham · European Respiratory Journal Open access	31 Oct 2004	1,030
6	Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins Helga H.J. Gerets, Karen Tilmant, Brigitte Gerin et al. · Cell Biology and Toxicology Open access	17 Jan 2012	704
7	The β-Secretase BACE1 in Alzheimer’s Disease Harald Juergen Hampel et al. · Biological Psychiatry Open access	12 Feb 2020	695
8	New avenues for anti-epileptic drug discovery and development Wolfgang Löscher, Henrik Klitgaard, Roy E. Twyman et al. · Nature Reviews Drug Discovery Review	20 Sep 2013	687
9	Developing Irreversible Inhibitors of the Protein Kinase Cysteinome Qingsong Liu, Yogesh A. Sabnis, Zheng Zhao et al. · Chemistry & Biology Open access	Feb 2013	675
10	Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960 Michael Worobey, Marlea Gemmel, Dirk E. Teuwen et al. · Nature Open access	Oct 2008	653
11	Imaging synaptic density in the living human brain Sjoerd J. Finnema, Nabeel Nabulsi, Tore Eid et al. · Science Translational Medicine	20 Jul 2016	621
12	The epidemiology of drug‐resistant epilepsy: A systematic review and meta‐analysis Linda Kalilani, Xuezheng Sun, Barbara Pelgrims et al. · Epilepsia ReviewOpen access	13 Nov 2018	600
13	Harmonization of strategies for the validation of quantitative analytical procedures P. Hubert, J.-J. Nguyen-Huu, Bruno Boulanger et al. · Journal of Pharmaceutical and Biomedical Analysis	17 Jun 2007	546
14	Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy Henrik Klitgaard, Alain Matagne, Jean Gérard Gobert et al. · European Journal of Pharmacology	Jul 1998	510
15	Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial Josef S Smolen, R. B. M. Landewé, Philip J. Mease et al. · Annals of the Rheumatic Diseases Open access	18 Nov 2008	496
16	Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial Bente Lomholt Langdahl et al. · The Lancet	26 Jul 2017	489
17	Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study Robert Landewé, Jürgen Braun, Atul A. Deodhar et al. · Annals of the Rheumatic Diseases Open access	6 Sep 2013	476
18	Levodopa‐induced dyskinesias Giovanni Fabbrini, Jonathan M. Brotchie, Francisco Grandas et al. · Movement Disorders	11 Apr 2007	466
19	Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) Philip J. Mease, Roy Fleischmann, Atul A. Deodhar et al. · Annals of the Rheumatic Diseases Open access	14 Aug 2013	461
20	Applications of single-cell RNA sequencing in drug discovery and development Bram Van de Sande, Joon Sang Lee, Euphemia Mutasa-Gottgens et al. · Nature Reviews Drug Discovery ReviewOpen access	28 Apr 2023	455
21	Modeling Parkinson’s Disease With the Alpha-Synuclein Protein Mónica Gómez-Benito, Noelia Granado, Patricia García‐Sanz et al. · Frontiers in Pharmacology Open access	23 Apr 2020	455
22	Multicenter Double‐Blind, Randomized, Placebo‐Controlled Trial of Levetiracetam as Add‐On Therapy in Patients with Refractory Partial Seizures Simon D. Shorvon, Armand Löwenthal, Diéter Janz et al. · Epilepsia	Sep 2000	450
23	Bimekizumab versus Secukinumab in Plaque Psoriasis Kristian Reich, Richard Bruce Warren, Mark Lebwohl et al. · New England Journal of Medicine	23 Apr 2021	427
24	Efficacy and Tolerability of Levetiracetam 3000 mg/d in Patients with Refractory Partial Seizures: A Multicenter, Double‐Blind, Responder‐Selected Study Evaluating Monotherapy Elinor Ben‐Menachem, Ursula Falter · Epilepsia	Oct 2000	410
25	Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study Xavier Mariette, Frauke Förger, Bincy P Abraham et al. · Annals of the Rheumatic Diseases Open access	30 Oct 2017	401
26	A General Copper‐Mediated Nucleophilic 18 F Fluorination of Arenes Matthew J. Tredwell, Sean Preshlock, Nicholas J. Taylor et al. · Angewandte Chemie International Edition	10 Jun 2014	391
27	Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective Mohamad Shebley et al. · Clinical Pharmacology & Therapeutics Open access	10 Jan 2018	390
28	Photoredox catalysis with aryl sulfonium salts enables site-selective late-stage fluorination Jiakun Li, Junting Chen, Ruocheng Sang et al. · Nature Chemistry	25 Nov 2019	386
29	Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression the Swiss Kidney Project on Genes in Hypertension (SKIPOGH) team, Matteo Trudu, Sylvie Janas et al. · Nature Medicine Open access	3 Nov 2013	380
30	Imaging robust microglial activation after lipopolysaccharide administration in humans with PET Christine M. Sandiego, Jean‐Dominique Gallezot, Brian P. Pittman et al. · Proceedings of the National Academy of Sciences Open access	18 Sep 2015	360
31	C9orf72 suppresses systemic and neural inflammation induced by gut bacteria Aaron Burberry, Michael F. Wells, Francesco Limone et al. · Nature Open access	13 May 2020	349
32	Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine Jérôme Hecq, Michel Deleers, D. Fanara et al. · International Journal of Pharmaceutics	6 Jul 2005	342
33	The anti‐epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA‐ and glycine‐gated currents J‐M Rigo, Grégory A. Hans, Laurent Nguyen et al. · British Journal of Pharmacology Open access	Jul 2002	340
34	Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study Roy Fleischmann, Jiří Vencovský, Ronald van Vollenhoven et al. · Annals of the Rheumatic Diseases Open access	18 Nov 2008	339
35	Harmonization of strategies for the validation of quantitative analytical procedures Ph. Hubert, J.-J. Nguyen-Huu, Bruno Boulanger et al. · Journal of Pharmaceutical and Biomedical Analysis	18 Jul 2007	332
36	Synthesis and Preclinical Evaluation of 11 C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain Nabeel Nabulsi, Joël Mercier, Daniel Holden et al. · Journal of Nuclear Medicine Open access	4 Feb 2016	331
37	A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis E. Michael Lewiecki, Tomasz Blicharski, Stefan Goemaere et al. · The Journal of Clinical Endocrinology & Metabolism Open access	20 Jun 2018	329
38	Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system Kun Zou, Li Zhao, Yong Zhang et al. · Acta Pharmacologica Sinica Open access	5 Dec 2016	316
39	Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review Cordula Stillhart, Katarina M. Vučićević, Patrick Augustijns et al. · European Journal of Pharmaceutical Sciences Open access	25 Feb 2020	315
40	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial Kristian Reich, Kim Alexander Papp, Andrew Blauvelt et al. · The Lancet	Feb 2021	313
41	Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial Kenneth B. Gordon, Peter Anthony Foley, James G. Krueger et al. · The Lancet	Feb 2021	295
42	Commonalities in epileptogenic processes from different acute brain insults: Do they translate? Pavel Klein et al. · Epilepsia Open access	15 Dec 2017	289
43	Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study James F. Howard et al. · The Lancet Neurology 187 authors	13 Apr 2023	276
44	Aryl Sulfonium Salts for Site‐Selective Late‐Stage Trifluoromethylation Fei Ye, Florian Berger, Hao Jia et al. · Angewandte Chemie International Edition Open access	7 Aug 2019	273
45	Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation Sophie Glatt, Dominique Baeten, TERRY S. BAKER et al. · Annals of the Rheumatic Diseases Open access	23 Dec 2017	267
46	Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants Joseph D. Symonds et al. · Brain Open access	21 Apr 2021	266
47	In Vivo Methods for the Assessment of Topical Drug Bioavailability Christophe Herkenne, Ingo Alberti, Aarti Naik et al. · Pharmaceutical Research Open access	5 Nov 2007	259
48	Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy Samuel Frank Berkovic, Robert C. Knowlton, Robert F. Leroy et al. · Neurology	12 Jul 2007	259
49	The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes Michel Noyer, Michel R. Gillard, Alain Matagne et al. · European Journal of Pharmacology	Nov 1995	256
50	The evolving role of investigative toxicology in the pharmaceutical industry François Pognan, Mario Beilmann, Harrie C. M. Boonen et al. · Nature Reviews Drug Discovery ReviewOpen access	13 Feb 2023	253

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.